Treatment of Sjögren Syndrome with Severe Autoimmune Thrombocytopenia (Platelet Count <50,000/mm³)

In Sjögren syndrome, severe autoimmune thrombocytopenia — defined by a platelet count below 50,000/mm³ — represents a serious systemic complication that requires a specific, severity-guided therapeutic approach.

Clinical Scenario

Sjögren syndrome presenting with severe autoimmune thrombocytopenia (platelet count <50,000/mm³). This haematological involvement indicates significant systemic disease activity and drives a more aggressive initial management strategy.

Treatment Approach (partial overview)

The protocol centres on glucocorticoid therapy, with the specific route — including an intravenous route for severe presentations — and regimen determined by the degree of thrombocytopenia.

Full treatment sequence, options, and dosing are available in the complete structured protocol.

Treatment Target

Therapeutic response is defined as a reduction of ≥3 points in the global ESSDAI score.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/annrheumdis-2019-216114

Severe haemolytic anaemia (<80 g/dL, <50 x10&sup9;/L); severe autoimmune thrombocytopenia (<50 000/mm³).

GCs should be used at the minimum dose and length of time necessary to control active systemic disease, administering pulses of methylprednisolone followed by doses of 0.5 mg/kg/d or lower as induction therapy in severe presentations, and doses <0.5 mg/kg/d in moderate/less-severe presentations, with a final target of withdrawing GCs in inactive patients as soon as possible or at least trying to target a maintenance dose of 5 mg/daily or less with the aid of GC-sparing immunosuppressive agents.

With respect to the definition of the therapeutic response in systemic SjS, the TF recommends using a reduction of ≥3 points in the global ESSDAI score.

View source ↗